Standardization for Subgroup Analysis in Randomized Controlled Trials

REFERENCES

• Food and Drug Administration . ( 1998 ). Guidance for Industry. Providing clinical evidence of effectiveness of human drug and biological products . Washington , DC : US Department of Health and Human Services .
   Google Scholar
• Groenwold , R. H. H. , Donders , A. R. T. , van der Heijden , G. J. M. G. , Hoes , A. W. , Rovers , M. M. ( 2009 ). Confounding of subgroup analyses in randomized data . Archives of Internal Medicine 169 : 1532 – 1533 .
   PubMedGoogle Scholar
• Robins , J. M. , Hernan , M. A. , Brumback , B. ( 2000 ). Marginal structural models and causal inference in epidemiology . Epidemiology 11 : 550 – 560 .
   PubMed Web of Science ®Google Scholar
• Rovers , M. M. , Glasziou , P. , Appelman , C. L. , Burke , P. , McCormick , D. P. , et al. ( 2006 ). Antibiotics for acute otitis media: A meta-analysis with individual patient data . Lancet 368 : 1429 – 1435 .
   PubMed Web of Science ®Google Scholar
• Sato , T. , Matsuyama , Y. ( 2003 ). Marginal structural models as a tool for standardization . Epidemiology 14 : 680 – 686 .
   PubMed Web of Science ®Google Scholar
• vanderWeele , T. J. , Knol , M. J. ( 2011 ). Interpretation of subgroup analyses in randomized trials: Heterogeneity versus secondary interventions . Annals of Internal Medicine 169 : 1532 – 1533 .
   Google Scholar